AnaptysBio, Inc.

NasdaqGS ANAB

AnaptysBio, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024: -31.51%

AnaptysBio, Inc. Return on Capital Employed (ROCE) is -31.51% for the Trailing 12 Months (TTM) ending September 30, 2024, a -22.25% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

AnaptysBio, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -25.78%, a -33.13% change year over year.
AnaptysBio, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -19.36%.
AnaptysBio, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -19.97%, a 2.17% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGS: ANAB

AnaptysBio, Inc.

CEO	Mr. Daniel R. Faga
IPO Date	Jan. 26, 2017
Location	United States
Headquarters	10770 Wateridge Circle
Employees	117
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Key trends

Past 5 years